The company’s financials have been in a slump for the past several years, but it reported growth in the second quarter of this year. New product launches are expected to sustain the uptick in growth in the company’s third quarter.
Here is how the company’s stock price breaks down by division:
• Interventional cardiology: 27.6 percent
• Pacemakers, defibrillators: 27.4 percent
• Endoscopy: 16.6 percent
• Peripheral interventions: 11.2 percent
• Urology and women’s health: 7.3 percent
• Neuromodulation: 7 percent
• Electrophysiology: 2.2 percent
• Divested businesses: 0.7 percent
More articles on gastroenterology:
5 gastroenterologists making the news
Menthol spray show to improve ADR, reduce peristalsis
3 ways gastroenterologists can demonstrate value
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
